RTTNews BiotechCodex · 实盘不做把握 6/10
北京时间·🕒 发布 21:55:53时区推断·⟳ 抓取 22:07:58·⚡ 决策 07-16 22:33:37 +25m39s·102.9 天前
Insmed公布TPIP治疗PAH的12个月开放标签延长期积极数据
Insmed（INSM.US）的TPIP 12个月OLE数据显示6MWD、NT-proBNP、WHO功能分级等指标持续改善，方向上利多公司管线价值。
📄 原文RTTNews Biotech↗ 原文
Insmed Incorporated (INSM) announced encouraging 12-month results from its ongoing open-label extension study of trepro…
不做 Insmed（INSM.US）
TPIP数据方向偏正面但属于已由公司8:00 ET公开的开放标签延长期数据，非获批/三期成功/收入落地；盘中股价已转跌，短线追多无edge，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- Insmed正式发布TPIP在PAH患者12个月OLE数据，并安排8:00 ET投资者电话，属于本次事件的一手源。市场反应:RTTNews早稿显示盘前INSM.US约111.91美元、涨1.91%。
- RTTNews在开盘后复述公司TPIP 12个月数据，已晚于官方发布与电话会。市场反应:报道中称INSM.US约108美元、跌1.65%。
- 2026-07-16 10:32 ET市场反应stock_quote非一手行情显示INSM.US最新105.54美元，较前收109.77美元跌3.85%，市场未确认正向重定价。市场反应:盘中下跌且量比约0.5，缺乏追多确认。
关键理由
- Insmed（INSM.US）的TPIP 12个月OLE数据显示6MWD、NT-proBNP、WHO功能分级等指标持续改善，方向上利多公司管线价值。
- 但该数据由公司在2026-07-16美东8:00投资者电话前后正式发布，RTTNews 9:55 ET报道已不是首发，且股价从盘前小涨转为盘中下跌。
- 量级上TPIP仍未获批、PALM-PAH三期才在推进；公司2025年已有约6.06亿美元收入、当前市值约229亿美元，本次不是立即商业化收入增量。
主要风险
- OLE为非安慰剂对照、疗效端点多为次要/探索性，公司自身也提示该单臂开放标签结果可能无法预测随机双盲三期结果。
- 事件公开后INSM.US盘中跌约3.85%，说明市场未把该数据当作足够强的新增正向 surprise。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-07-16 · 影响 weakens
公司前瞻风险披露明确指出OLE为单臂开放标签设计，次要/探索性疗效端点可能高估真实疗效，且未必预测PALM-PAH三期结果。
检索:Insmed TPIP OLE study risk non-placebo controlled Phase 3 predictive risk 原文 ↗ - 做多前查反向 · 来源 stock_quote · 日期 2026-07-16 · 影响 weakens
INSM.US盘中105.54美元、跌3.85%，与利好方向相反，说明公开数据后市场没有给出可跟随的正向确认。
检索:INSM.US stock_quote full
工具调用 · 历史记录,结果未知(1 种)
- stock_quote · 结果未知
原文全文
展开原文 · 2,344 字
Insmed Incorporated (INSM) announced encouraging 12-month results from its ongoing open-label extension study of treprostinil palmitil inhalation powder (TPIP), a once-daily therapy being developed for pulmonary arterial hypertension (PAH).
The findings highlight sustained improvements across key efficacy measures and reinforce TPIP's potential as a next-generation prostanoid treatment.
The open-label extension study is designed to evaluate long-term safety, tolerability, and effectiveness of TPIP over 24 months in patients who completed the lead-in PAH studies. Results showed continued benefit in six-minute walk distance, NT-proBNP levels, WHO functional class, and REVEAL Lite 2.0 score at Month 12. Patients who switched from placebo to TPIP achieved outcomes comparable to those who remained on TPIP throughout the study.
Gene Sullivan, M.D., Chief Product Strategy Officer of Insmed, said: "These data represent an important milestone in our efforts to fully harness the potential of treprostinil and provide meaningful benefit to patients with pulmonary arterial hypertension. TPIP demonstrated sustained improvement across all efficacy endpoints and was well tolerated with no newly identified safety signals."
TPIP is a novel inhaled formulation of treprostinil designed for once-daily dosing, aiming to improve convenience and adherence compared with existing prostanoid therapies. Doses up to 1,280 µg once daily were permitted in the study, with no new safety concerns identified.
Insmed noted that these results, combined with earlier Phase 2b data, support TPIP's potential to become the prostanoid of choice for PAH patients. The company is advancing its Phase 3 PALM-PAH study to further evaluate the therapy's efficacy and long-term safety.
INSM has traded between $90.39 and $212.75 over the past year. The stock is currently trading at $108.00, down 1.65%.
For comments and feedback contact: editorial@rttnews.com
Business News
July 13, 2026 10:12 ET The week saw the release of the minutes of the Federal Reserve’s latest monetary policy session, foreign trade figures and survey data on manufacturing and services in the U.S. External trade data from Germany was the highlight in Europe, while the latest macroeconomic projections from the Asian Development Bank and the International Monetary Fund gained attention.
The findings highlight sustained improvements across key efficacy measures and reinforce TPIP's potential as a next-generation prostanoid treatment.
The open-label extension study is designed to evaluate long-term safety, tolerability, and effectiveness of TPIP over 24 months in patients who completed the lead-in PAH studies. Results showed continued benefit in six-minute walk distance, NT-proBNP levels, WHO functional class, and REVEAL Lite 2.0 score at Month 12. Patients who switched from placebo to TPIP achieved outcomes comparable to those who remained on TPIP throughout the study.
Gene Sullivan, M.D., Chief Product Strategy Officer of Insmed, said: "These data represent an important milestone in our efforts to fully harness the potential of treprostinil and provide meaningful benefit to patients with pulmonary arterial hypertension. TPIP demonstrated sustained improvement across all efficacy endpoints and was well tolerated with no newly identified safety signals."
TPIP is a novel inhaled formulation of treprostinil designed for once-daily dosing, aiming to improve convenience and adherence compared with existing prostanoid therapies. Doses up to 1,280 µg once daily were permitted in the study, with no new safety concerns identified.
Insmed noted that these results, combined with earlier Phase 2b data, support TPIP's potential to become the prostanoid of choice for PAH patients. The company is advancing its Phase 3 PALM-PAH study to further evaluate the therapy's efficacy and long-term safety.
INSM has traded between $90.39 and $212.75 over the past year. The stock is currently trading at $108.00, down 1.65%.
For comments and feedback contact: editorial@rttnews.com
Business News
July 13, 2026 10:12 ET The week saw the release of the minutes of the Federal Reserve’s latest monetary policy session, foreign trade figures and survey data on manufacturing and services in the U.S. External trade data from Germany was the highlight in Europe, while the latest macroeconomic projections from the Asian Development Bank and the International Monetary Fund gained attention.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。